Suppr超能文献

严重急性呼吸综合征冠状病毒2(SARS-CoV-2)在二级生物安全水平下的实验室生物安全措施,特别提及了其传染性更强的变异株。

Laboratory biosafety measures of SARS-CoV-2 at containment level 2 with particular reference to its more infective variants.

作者信息

Naeem Wafa, Zeb Habiba, Rashid Muhammad Ibrahim

机构信息

Department of Molecular Biology & Genetics, Institute of Basic Medical Sciences, Khyber Medical University, Peshawar 25000, Pakistan.

出版信息

Biosaf Health. 2022 Feb;4(1):11-14. doi: 10.1016/j.bsheal.2021.12.005. Epub 2021 Dec 28.

Abstract

The novel betacoronavirus (Severe Acute Respiratory Syndrome Coronavirus 2, SARS-CoV-2) is a pathogen that causes deadly respiratory disease named coronavirus disease 2019 (COVID-19). The incidence of this disease has increased in the last few months affecting 257,832,881 people in 221 countries and 51,68,069 deaths worldwide according to Worldometer at 04:03 GMT on November 22, 2021. Thus, the emergence of this disease creates a challenge for health care providers in handling this pathogen and reducing its risk of transmission. In developing countries, this virus is treated in biosafety level 2 laboratories, where a high concentration of pathogen can easily affect the laboratory staff and cause the spread of this disease. Based on the epidemiology and characteristics of the SARS-CoV-2 virus already discussed in recent studies, we will provide biosafety guidelines and suggestions for safe handling and transportation of the SARS-CoV-2 virus in dealing with the current pandemic situation with a focus on increased infectivity of emerging new variants.

摘要

新型β冠状病毒(严重急性呼吸综合征冠状病毒2,SARS-CoV-2)是一种引发名为2019冠状病毒病(COVID-19)的致命呼吸道疾病的病原体。根据世界ometers网站2021年11月22日04:03 GMT的数据,在过去几个月中,这种疾病的发病率有所上升,影响了221个国家的257,832,881人,全球有51,68,069人死亡。因此,这种疾病的出现给医护人员应对这种病原体并降低其传播风险带来了挑战。在发展中国家,这种病毒在生物安全二级实验室中进行处理,在那里高浓度的病原体很容易感染实验室工作人员并导致这种疾病的传播。基于近期研究中已经讨论过的SARS-CoV-2病毒的流行病学和特征,我们将提供生物安全指南以及关于在当前大流行情况下安全处理和运输SARS-CoV-2病毒的建议,重点关注新出现的变异毒株不断增加的传染性。

相似文献

1
Laboratory biosafety measures of SARS-CoV-2 at containment level 2 with particular reference to its more infective variants.
Biosaf Health. 2022 Feb;4(1):11-14. doi: 10.1016/j.bsheal.2021.12.005. Epub 2021 Dec 28.
2
Laboratory Biosafety Considerations of SARS-CoV-2 at Biosafety Level 2.
Health Secur. 2020 May/Jun;18(3):232-236. doi: 10.1089/hs.2020.0021. Epub 2020 Jun 9.
3
Laboratory biosafety measures involving SARS-CoV-2 and the classification as a Risk Group 3 biological agent.
Pathology. 2020 Dec;52(7):790-795. doi: 10.1016/j.pathol.2020.09.006. Epub 2020 Sep 30.
5
SARS-CoV-2 in environmental perspective: Occurrence, persistence, surveillance, inactivation and challenges.
Chem Eng J. 2021 Feb 1;405:126893. doi: 10.1016/j.cej.2020.126893. Epub 2020 Sep 4.
6
The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
J Biol Regul Homeost Agents. 2021 Jan-Feb;35(1):1-4. doi: 10.23812/21-3-E.
7
Biosafety threats of the rapidly established labs for SARS-CoV-2 tests in China.
Environ Int. 2020 Oct;143:105964. doi: 10.1016/j.envint.2020.105964. Epub 2020 Jul 14.
8
[Principles and suggestions on biosafety protection of biological specimen preservation during prevalence of COVID-19].
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):170-177. doi: 10.3785/j.issn.1008-9292.2020.02.04.
9
The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A review of the current global status.
J Infect Public Health. 2020 Nov;13(11):1601-1610. doi: 10.1016/j.jiph.2020.07.011. Epub 2020 Aug 4.

引用本文的文献

2
Molecular Diagnosis of COVID-19; Biosafety and Pre-analytical Recommendations.
Iran J Pathol. 2023 Summer;18(3):244-256. doi: 10.30699/IJP.2023.1988405.3061. Epub 2023 Jul 16.
3
Biosafety and biosecurity challenges during the COVID-19 pandemic and beyond.
Front Bioeng Biotechnol. 2023 Mar 1;11:1117316. doi: 10.3389/fbioe.2023.1117316. eCollection 2023.
5
Baculovirus displaying SARS-CoV-2 spike RBD promotes neutralizing antibody production in a mouse model.
J Genet Eng Biotechnol. 2023 Feb 9;21(1):16. doi: 10.1186/s43141-023-00472-2.

本文引用的文献

1
COVID-19: A Risk Assessment Perspective.
J Chem Health Saf. 2020 May 11;27(3):160-169. doi: 10.1021/acs.chas.0c00035. eCollection 2020 May 26.
3
Recent advances in the diagnosis of COVID-19: a bird's eye view.
Expert Rev Mol Diagn. 2021 May;21(5):475-491. doi: 10.1080/14737159.2021.1874354. Epub 2021 Mar 1.
5
Standard Operating Procedure for Specimen Collection, Packaging and Transport for Diagnosis of SARS-COV-2.
JNMA J Nepal Med Assoc. 2020 Jul 31;58(228):627-629. doi: 10.31729/jnma.5260.
6
Biosafety Concerns During the Collection, Transportation, and Processing of COVID-19 Samples for Diagnosis.
Arch Med Res. 2020 Oct;51(7):623-630. doi: 10.1016/j.arcmed.2020.08.007. Epub 2020 Sep 12.
7
The energy and environmental footprints of COVID-19 fighting measures - PPE, disinfection, supply chains.
Energy (Oxf). 2020 Nov 15;211:118701. doi: 10.1016/j.energy.2020.118701. Epub 2020 Aug 27.
9
Clinical Samples for SARS-CoV-2 Detection: Review of the Early Literature.
Clin Microbiol Newsl. 2020 Aug 1;42(15):121-127. doi: 10.1016/j.clinmicnews.2020.07.001. Epub 2020 Jul 23.
10
Gastrointestinal symptoms associated with COVID-19: impact on the gut microbiome.
Transl Res. 2020 Dec;226:57-69. doi: 10.1016/j.trsl.2020.08.004. Epub 2020 Aug 20.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验